THOMAS WILLIAM EVANS
Occupational Therapy in San Diego, CA
License number
Pennsylvania OP002632L
Category
Occupational Therapy
Type
Occupational Therapy Assistant
Address
Address
2
San Diego, CA 92106
Pennsylvania
Pennsylvania
Personal information
See more information about THOMAS WILLIAM EVANS at radaris.comName
Address
Phone
513 Coleman Dr, Lompoc, CA 93436
516 Pittston Ave APT 3, Scranton, PA 18505
515 Aspen Woods Dr, Yardley, PA 19067
5103 Bigler Rd, Clearfield, PA 16830
5326 Orchard Park Ln, Santa Barbara, CA 93111
Professional information
Richard Realty Groups
Position:
Realtor at Richard Realty Groups, Inc.
Location:
Greater San Diego Area
Industry:
Real Estate
Work:
Richard Realty Groups, Inc.
since Jan 2011
-
Realtor
Keller Williams Realty
Apr 2006 - Jan 2010
-
Realtor
Independent Graphic Design Professional
Position:
Graphic Design at Evans Mixed Media
Location:
Greater San Diego Area
Industry:
Graphic Design
Work:
Evans Mixed Media
since Oct 2012
-
Graphic Design
AngelPrint.com
Sep 2007 - Sep 2012
-
Production
Education:
Pallomar College
Skills:
Print Production, Bindery, Graphic Design, Logo Design, Corporate Identity, Typography, Brochures, Illustrator, Layout, Posters, Illustration, InDesign, Adobe Creative Suite, Visual Communication, Creative Direction, Business Cards, Photoshop, Flyers
Influenza Virus Vaccine Composition And Methods Of Use
US Patent:
2006002, Feb 2, 2006
Filed:
May 18, 2005
Appl. No.:
11/131479
Inventors:
Catherine Luke - Frederick MD, US
Adrian Vilalta - San Diego CA, US
Mary Wloch - San Diego CA, US
Thomas Evans - San Diego CA, US
Andrew Geall - San Marcos CA, US
Gretchen Jimenez - San Diego CA, US
Adrian Vilalta - San Diego CA, US
Mary Wloch - San Diego CA, US
Thomas Evans - San Diego CA, US
Andrew Geall - San Marcos CA, US
Gretchen Jimenez - San Diego CA, US
International Classification:
C12Q 1/70, C07H 21/04, C12P 21/06, A61K 39/145, C07K 14/11
US Classification:
435005000, 435069100, 435456000, 435325000, 424209100, 530350000, 536023720
Abstract:
The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo, into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount.
Influenza Virus Vaccine Composition And Methods Of Use
US Patent:
2010019, Aug 5, 2010
Filed:
Jan 15, 2010
Appl. No.:
12/688614
Inventors:
Catherine J. Luke - Frederick MD, US
Adrian Vilalta - San Diego CA, US
Mary K. Wloch - San Diego CA, US
Thomas G. Evans - San Diego CA, US
Andrew J. Geall - San Marcos CA, US
Gretchen S. Jimenez - San Diego CA, US
Adrian Vilalta - San Diego CA, US
Mary K. Wloch - San Diego CA, US
Thomas G. Evans - San Diego CA, US
Andrew J. Geall - San Marcos CA, US
Gretchen S. Jimenez - San Diego CA, US
Assignee:
Vical Incorporated - San Diego CA
International Classification:
A61K 31/7052, C07H 21/00, C12N 15/63, A61P 31/12, A61P 37/04
US Classification:
514 44 R, 536 231, 4353201
Abstract:
The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo, into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount.
Influenza Virus Vaccine Composition And Methods Of Use
US Patent:
8128938, Mar 6, 2012
Filed:
Aug 17, 2007
Appl. No.:
11/892016
Inventors:
Catherine J. Luke - Rockville MD, US
Adrian Vilalta - San Diego CA, US
Mary K. Wloch - San Diego CA, US
Thomas G. Evans - San Diego CA, US
Andrew J. Geall - San Marcos CA, US
Gretchen S. Jimenez - San Diego CA, US
Adrian Vilalta - San Diego CA, US
Mary K. Wloch - San Diego CA, US
Thomas G. Evans - San Diego CA, US
Andrew J. Geall - San Marcos CA, US
Gretchen S. Jimenez - San Diego CA, US
Assignee:
Vical Incorporated - San Diego CA
International Classification:
A61K 39/145, A61K 31/7088, C12N 15/44, C12N 15/36
US Classification:
4242091, 514 44 R, 536 2372, 4353201
Abstract:
The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo, into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount.
Influenza Virus Vaccine Composition And Methods Of Use
US Patent:
2012012, May 24, 2012
Filed:
Sep 30, 2011
Appl. No.:
13/250508
Inventors:
Catherine J. LUKE - Frederick MA, US
Adrian Vilalta - San Diego CA, US
Mary K. Wloch - San Diego CA, US
Thomas G. Evans - San Diego CA, US
Andrew J. Geall - San marcos CA, US
Gretchen S. Jimenez - San Diego CA, US
Adrian Vilalta - San Diego CA, US
Mary K. Wloch - San Diego CA, US
Thomas G. Evans - San Diego CA, US
Andrew J. Geall - San marcos CA, US
Gretchen S. Jimenez - San Diego CA, US
Assignee:
Vical Incorporated - San Diego CA
International Classification:
A61K 39/145, C12N 15/63, A61P 31/16, C12N 15/44, C12N 15/51
US Classification:
4242091, 536 2372, 4353201
Abstract:
The present invention is directed to compositions and methods for enhancing the immune response of a human in need of protection against influenza virus (IV) infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof, or a protein encoded thereby. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount.